Prescribe Right
Prescribe Right
  • Home
  • About
    • Endorsements
    • Published Articles
    • Consulting
    • Effective Pharmacotherapy
  • Pipeline News
    • Podcast
    • Recent Tweets
  • Pharmaceutical Pipeline Tracker
    • Access Pharmaceutical Pipeline Tracker
    • Pharmaceutical Pipeline Tracker Demo
    • Sample Drug Review
    • Case Studies >
      • Monitoring Drugs With PDUFA Dates
      • Monitoring Drugs By Therapeutic Category
      • Monitoring by Indication
      • Research a Single Drug
    • Sample Searches >
      • Single Drug Report Sample
      • Indication Search Sample
      • Drug Class Search Sample
      • Therapeutic Area Search Sample
      • Company Search Sample
  • COVID-19
    • COVID-19 Updates
    • COVID-19 Vaccines
    • COVID-19 Antivirals
    • COVID-19 Monoclonal Antibodies
    • COVID-19 Plasma Products
    • COVID-19 Anti-Inflammatories
    • Remdesivir
    • Ivermectin
  • Contact Us
  • Home
  • About
    • Endorsements
    • Published Articles
    • Consulting
    • Effective Pharmacotherapy
  • Pipeline News
    • Podcast
    • Recent Tweets
  • Pharmaceutical Pipeline Tracker
    • Access Pharmaceutical Pipeline Tracker
    • Pharmaceutical Pipeline Tracker Demo
    • Sample Drug Review
    • Case Studies >
      • Monitoring Drugs With PDUFA Dates
      • Monitoring Drugs By Therapeutic Category
      • Monitoring by Indication
      • Research a Single Drug
    • Sample Searches >
      • Single Drug Report Sample
      • Indication Search Sample
      • Drug Class Search Sample
      • Therapeutic Area Search Sample
      • Company Search Sample
  • COVID-19
    • COVID-19 Updates
    • COVID-19 Vaccines
    • COVID-19 Antivirals
    • COVID-19 Monoclonal Antibodies
    • COVID-19 Plasma Products
    • COVID-19 Anti-Inflammatories
    • Remdesivir
    • Ivermectin
  • Contact Us
Pipeline News and Updates
Picture

Update for January 18, 2022

1/18/2022

 
Access 53 recently approved and available drugs and 22 investigational drugs on the short list for approval.

Last week we added 12 new drugs to the knowledgebase:
  1. Spesolimab to treat generalized pustular psoriasis flares
  2. Nemvaleukin to treat platinum-resistant ovarian cancer
  3. Parsaclisib to treat relapsed or refractory non-hodgkin lymphomas
  4. Isaralgagene civaparvovec to treat Fabry disease
  5. Izokibep to treat ankylosing spondylitis
  6. Icosabutate to treat nonalcoholic steatohepatitis (NASH)
  7. Ensartinib to treat ALK-positive non-small cell lung cancer (NSCLC)
  8. Simufilam to treat Mild to moderate Alzheimer's Disease
  9. Ensovibep to treat COVID-19
  10. Rencofilstat to treat nonalcoholic steatohepatitis (NASH)
  11. C-CAR039 to treat relapsed or refractory diffuse large B-cell lymphoma (DLBCL)
  12. BDC-1001 to treat HER2-expressing solid tumors
The Prescribe Right Pharmaceutical Pipeline Tracker now allows you to track 970 pipeline and recently approved drugs by the following search parameters:
  • 800 Indications
  • 249 Approvals
  • 663 manufacturers
  • 26 Therapeutic classes
  • Drugs with PDUFA Dates
  • Recently approved drugs
Regulatory Update 

The FDA approved abrocitinib (Cibinqo, Pfizer), on 1/14/2022, for the treatment of adults with refractory, moderate-to-severe atopic dermatitis (AD) whose disease is not adequately controlled with other systemic therapies. Like other JAK inhibitors, abrocitinib was approved with a boxed warning regarding the increased risk for serious infections, mortality, malignancy, major cardiovascular events and thrombosis.
 
Announced Research Updates 

Sarepta announced data from 20 patients enrolled in Part 2 of a 48-week, 41 patient, Phase II trial, where treatment with delandistrogene moxeparvovec improved the NSAA score by two points compared to a 103 patient, weighted external control group (1.3 point increase vs 0.7 point decrease).

We also added six new published research updates that subscribers can review
  • Adding camrelizumab to carboplatin plus paclitaxel to treat advanced squamous non-small cell lung cancer.
  • The combination of camrelizumab and apatinib in the treatment of advanced esophageal squamous cell carcinoma.
  • Phase II results for the J&J ebola vaccine.
  • Adding spartalizumab to dabrafenib and trametinib to treat BRAF V600-mutant unresectable or metastatic melanoma.
  • Melflufen compared to pomalidomide to treat relapsed or refractory multiple myeloma patients who are receiving dexamethasone.
  • Does adding radiotherapy to tremelimumab plus durvalumab improve the overall response rate in the treatment of metastatic non-small cell lung cancer resistant to PD-1 and PD-L1 targeted therapy?
Check out our new lower subscription rates and don't miss out on these clinical updates.

Comments are closed.
    Stay informed, subscribe to the 
    ​
    Prescribe Right Pharmaceutical Pipeline Tracker
    Latest Tweets from Prescribe Right

    Archives

    January 2023
    December 2022
    October 2022
    September 2022
    August 2022
    July 2022
    June 2022
    May 2022
    April 2022
    March 2022
    February 2022
    January 2022
    December 2021
    November 2021
    October 2021
    September 2021
    August 2021
    July 2021
    June 2021
    May 2021
    April 2021
    March 2021
    February 2021
    January 2021
    December 2020
    November 2020
    October 2020
    September 2020
    August 2020
    July 2020
    June 2020
    May 2020
    April 2020
    March 2020
    February 2020
    January 2020
    December 2019
    November 2019
    October 2019
    September 2019
    August 2019
    July 2019
    June 2019
    May 2019
    April 2019
    March 2019
    February 2019
    January 2019
    December 2018
    November 2018
    October 2018
    September 2018
    August 2018
    June 2018
    May 2018
    April 2018
    March 2018
    February 2018
    January 2018
    December 2017
    November 2017
    October 2017
    September 2017
    August 2017
    August 2015

    RSS Feed

Services

Pharmaceutical Pipeline Tracker​
Consulting

Company

About
Blog
Tweets

Support

Contact
© COPYRIGHT 2015. ALL RIGHTS RESERVED.